The biopharma industry is facing significant shifts in go-to-market models due to regulatory uncertainty and access challenges. Direct-to-consumer (DTC) advertising has been effective in creating awareness at the top of the funnel and initiating actions early in the patient journey. However, converting this awareness into actual conversions at the pharmacy level has been a challenge. Despite substantial investments in DTC campaigns, pharmaceutical companies are experiencing increasing prescription abandonment rates at pharmacies, often attributed to high out-of-pocket costs and frequent brand switches.
While the healthcare spending in the U.S. continues to rise annually, patient outcomes are not improving significantly, partly due to escalating access barriers. Formulary restrictions on branded drugs have surged, with a substantial increase in utilization management tools like prior authorization. This has led to a higher number of patients facing out-of-pocket costs exceeding $250 for a single prescription, resulting in a significant portion of prescriptions going unfilled each year. The rise of the “patient-as-payer” model has further exacerbated financial burdens on consumers, with formulary exclusions and increasing costs being key challenges.
Despite the biopharmaceutical industry investing billions annually in copay assistance and support programs, there remains a disconnect between these resources and patient awareness. Only a small percentage of Americans are aware of the existence of such support programs, highlighting a crucial gap that needs to be addressed urgently. Healthcare providers are increasingly under pressure to switch patients to lower-cost alternatives, even if they are not AB-rated, due to cost pressures and payer mandates, potentially compromising patient outcomes.
Pharmaceutical companies continue to invest heavily in top-of-funnel tactics to increase brand awareness, with the expectation that this awareness will translate into actions. However, the current model is faltering, as patients are often unable to access prescribed medications due to financial barriers or insurance issues. This gap between creating awareness and ensuring access underscores the need for a shift in approach towards empowering healthcare providers to navigate cost and access barriers effectively.
To address these challenges, embedding healthcare provider solutions directly into the point of care is crucial. Digital affordability tools, such as integrated copay cards and patient access support, can significantly reduce patient out-of-pocket costs, improve adherence, and ease the burden on healthcare providers. By integrating these tools into the prescribing workflow, healthcare providers can offer immediate support and counseling to patients, making access and affordability integral parts of the care process.
In conclusion, the biopharma industry must recognize the importance of addressing access and affordability challenges alongside enhancing brand awareness. Collaboration among stakeholders, including pharmaceutical companies, healthcare providers, technology partners, and platforms like GoodRx, is essential to eliminate barriers, streamline prescription fulfillment, and ensure timely access to treatments. By fostering a digitally connected, patient-first ecosystem built on shared purpose and innovation, the industry can work towards a healthcare system that delivers better outcomes for all stakeholders.
Key Takeaways:
– Regulatory uncertainty and access challenges are reshaping go-to-market models in the biopharma industry.
– Addressing the gap between awareness and access is crucial to improving patient outcomes and reducing prescription abandonment rates.
– Collaborative efforts among stakeholders are essential to overcome barriers and enhance access and affordability in biopharma.
– Integrating digital affordability tools into the healthcare workflow can significantly reduce patient out-of-pocket costs and improve adherence.
Tags: regulatory, clinical trials, biopharma, antibody-drug conjugates
Read more on biopharmadive.com